Weber Christian F, Adam Elisabeth H, Meybohm Patrick, Müller Markus M, Seifried Erhard, Zacharowski Kai
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt.
Anasthesiol Intensivmed Notfallmed Schmerzther. 2013 May;48(5):314-7. doi: 10.1055/s-0033-1347154. Epub 2013 Jun 11.
In patients suffering from massive bleeding, transfusion of allogenic blood products (red blood cells, fresh frozen plasma and platelets) and the application of other hemostatic therapy in form of coagulation factor concentrates represent therapeutic approaches to optimize hemostasis and to restore and assure tissue oxygenation. In accordance to the "Helsinki declaration on patient safety" of the European Society of Anaesthesiology, this review article describes a clinical practice guideline for the treatment of patients requiring massive transfusion that was implemented at the University hospital Frankfurt in 2013. Our guideline may be used as a template for other institutions.
对于大量出血的患者，输注异体血液制品（红细胞、新鲜冰冻血浆和血小板）以及应用凝血因子浓缩物形式的其他止血疗法是优化止血、恢复并确保组织氧合的治疗方法。根据欧洲麻醉学会的《关于患者安全的赫尔辛基宣言》，本文综述描述了2013年在法兰克福大学医院实施的针对需要大量输血患者的临床实践指南。我们的指南可用作其他机构的模板。
